Article Text

PDF
THU0521 Dual Neutralization of TNF and IL-17 with A Dvd-Ig Protein is Efficacious in Collagen Induced Arthritis
  1. C. Cuff1,
  2. S. Bryant2,
  3. M. Hugunin3,
  4. R. Kamath2,
  5. J. Voss3,
  6. L. Olson1,
  7. C.-M. Hsieh1
  1. 1Immunology Discovery
  2. 2Pharmacology
  3. 3Molecular & Cellular Pharmacology, Abbvie Bioresearch Center, Worcester, United States

Abstract

Background TNF blockade has provided significant benefit to many patients with rheumatoid arthritis. Nonetheless, a substantial unmet medical need remains for patients who do not respond adequately to this treatment. We and others have demonstrated that dual neutralization of TNF and IL-17 provides greater efficacy than blocking either cytokine alone in mouse collagen induced arthritis 1,2,3.

Objectives The goal of these studies was to determine whether an anti-TNF/IL-17 Dual Variable Domain immunoglobulin (DVD-Ig™) protein would be efficacious in a pre-clinical model of arthritis.

Methods A surrogate anti-mouse TNF and IL-17 DVD-Ig™ protein was engineered from two variable domains that bind TNF and IL-17, respectively. The resulting DVD-Ig™ has high affinity and potency to both targets and is capable of simultaneous binding of TNF and IL-17 as determined by surface plasmon resonance. The efficacy of this anti-mouse TNF/IL-17 DVD-Ig™ molecule was tested in the mouse collagen induced arthritis model. Animals were treated with vehicle anti-TNF antibody (Ab) (8C11, 12 mg/kg), anti-IL-17 Ab (MAB421, 12 mg/kg), anti-TNF + anti-IL-17 Abs (12/12 mg/kg), or an anti-mouse TNF/IL-17 DVD-Ig™ protein (16 mg/kg) twice a week for 3 weeks beginning at the onset of disease. The effect on disease was measured by paw swelling, histologic evaluation, as well as micro-CT measurement of bone volume.

Results Neutralization of either mouse TNF or IL-17 by their respective Abs alone resulted in a significant but partial inhibition of paw swelling (43 and 24%, respectively, p<0.05). However, neutralization of both cytokines by administration of a combination of anti-TNF and anti-IL-17 mAbs significantly reduced arthritic score to a greater extent 64%; p<0.05) and was also more effective at preventing bone destruction vs treatment with anti-TNF alone as determined by micro-CT analysis (80% vs 49 or 53%, p<0.05). Treatment with an anti-mouse TNF/IL-17 DVD-Ig™ protein inhibited inflammation, swelling, cartilage and bone destruction to a similar level as that achieved with the combination treatment with both Abs.

Conclusions These data demonstrate that dual blockade of TNF and IL-17 with a DVD-Ig™ molecule is efficacious in a pre-clinical model of arthritis and support the rationale to clinically evaluate the anti-human TNF/IL-17 DVD-Ig protein, ABT-122, in rheumatoid arthritis and other inflammatory disorders.

References

  1. Cuff et al 2013 Annual Meeting, Abstract 948.

  2. Koenders et al., Arthritis Rheum. 2011;63(8):2329-39.

  3. Alzabin et al Ann Rheum Dis. 2012;71(10):1741-8.

Disclosure of Interest : C. Cuff Shareholder of: Abbvie, Employee of: AbbVie Bioresearch Center, S. Bryant Employee of: AbbVie Bioresearch Center, M. Hugunin Shareholder of: Abbvie, Employee of: AbbVie Bioresearch Center, R. Kamath Shareholder of: Abbvie, Employee of: AbbVie Bioresearch Center, J. Voss Shareholder of: Abbvie, Employee of: AbbVie Bioresearch Center, L. Olson Shareholder of: Abbvie, Employee of: AbbVie Bioresearch Center, C.-M. Hsieh Shareholder of: Abbvie, Employee of: AbbVie Bioresearch Center

DOI 10.1136/annrheumdis-2014-eular.5383

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.